Abbott
AbbVie ‘pleased’ with first year
February 3, 2014Sales and Marketing AbbVie, Abbott, CLL, EMA, HIV, Humira
Rheumatoid arthritis treatment Humira – as expected – has driven AbbVie in its first year as a standalone company, accounting …
Former Abbott head now director for UDG Healthcare
December 19, 2013Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Abbott, udg healthcare
Healthcare services provider UDG Healthcare has appointed Brendan McAtamney to be its executive director and announces two other senior hires. …
Robert Brooks joins Achilles from Abbott
September 10, 2013Manufacturing and Production, Research and Development, Sales and Marketing AbbVie, Abbott, achilles, brook
Supply chain firm Achilles has hired Dr Robert Brooks to be a Business Development director from pharma firm Abbott. Brooks …
Marginal sales increase for Abbott
July 18, 2013Sales and Marketing AbbVie, Abbott, Q2
Abbott’s second quarter results saw the company buffeted by currency exchange issues – primarily the yen weakening against the US …
United Drug hires Abbott VP
June 19, 2013Manufacturing and Production, Research and Development, Sales and Marketing Abbott, United Drug
Healthcare services firm United Drug has appointed Brendan McAtamney as chief operating officer with effect from September. McAtamney will be …
Orencia matches Humira
June 13, 2013Sales and Marketing AbbVie, Abbott, Humira, Orencia, RA
Bristol-Myers Squibb is hoping its biologic Orencia can grab a little more of the rheumatoid arthritis market after demonstrating non-inferiority …
Sales rise for AbbVie
April 30, 2013Sales and Marketing AbbVie, Abbott
AbbVie has released its first financial results as a standalone company since separating from Abbott as an $18 billion biopharma …
AbbVie guards Humira data
March 13, 2013Sales and Marketing AbbVie, Abbott, Humira, RA, transparency
AbbVie has issued two injunctions against the European Medicines Agency to prevent the regulator revealing data about rheumatoid arthritis drug …
Abbott seeks leukemia test
February 25, 2013Sales and Marketing AbbVie, Abbott, Janssen
Abbott is to team up with Janssen Biotech and biopharma firm Pharmacyclics to seek a diagnostic test for leukemia patients. …
Sanofi won’t follow trend for spin-offs
February 8, 2013Sales and Marketing Abbott, Pfizer, Sanofi, Viehbacher
Sanofi’s chief executive Chris Viehbacher says the firm plans to maintain its portfolio of business divisions for the foreseeable future, …
Abbott finishes strongly before spin-off
January 25, 2013Sales and Marketing AbbVie, Abbott, Q4 2012
Abbott has presented its full-year results for 2012 – the last in which many of its products will appear, following …
AbbVie splits from Abbott
January 7, 2013Sales and Marketing AbbVie, Abbott, HIV, Humira
AbbVie, the new $18 billion biopharma company which includes many of Abbott’s most high profile products, has finally launched. Abbott …
Another indication for Humira
November 28, 2012Sales and Marketing Abbott, Crohn's, EU, Humira
Abbott’s Humira has received its ninth indication in Europe with approval to treat youngsters suffering from the inflammatory bowel disease …
Abbott pulls kidney disease trial
October 22, 2012Research and Development, Sales and Marketing Abbott, Reata, kidney
Abbott has terminated its Phase III trial of bardoxolone methyl in patients with kidney disease and diabetes after concerns over …
Humira continues to drive Abbott
October 22, 2012Sales and Marketing AbVie, Abbott, Humira, RA
Abbott Laboratories’ rheumatoid arthritis drug Humira has once again shown its value to the company with a strong performance in …
Latest content
NIHR chief scientific adviser visits Huddersfield health innovation campus
One in three UK women with migraine say symptoms taken less seriously
Report highlights scope to expand day surgery
Sygnature formalises drug discovery collaboration with X-Chem
Codis appoints Steven Facer as chief commercial officer
